3.16

3.36% -0.11

After Hours: 3.20 0.04 +1.27%

Dare Bioscience Inc (DARE)

Overview News Price History Financials Discussions Forecast Stock Split

Dare Bioscience Inc stock is traded at $3.16, with a volume of 1.57M. It is down -3.36% in the last 24 hours and up +74.59% over the past month. Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.

Previous Close:

$3.27

Open:

$3.37

24h Volume:

1.57M

Relative Volume:

3.44

Market Cap:

$46.01M

Revenue:

$1.03M

Net Income/Loss:

$-13.40M

P/E Ratio:

-2.3734

EPS:

-1.3314

Net Cash Flow:

$-10.27M

1W Performance:

+50.48%

1M Performance:

+74.59%

6M Performance:

+74.59%

1Y Performance:

+8.97%

1-Day Range:

$2.69

$3.40

1-Week Range:

$2.07

$3.78

52-Week Range:

$1.27

$9.19

Dare Bioscience Inc Stock (DARE) Company Profile

Name

Dare Bioscience Inc

Sector

Healthcare (1111)

Industry

Biotechnology (621)

Phone

858-926-7655

Address

3655 NOBEL DRIVE, SAN DIEGO, CA

Employee

Twitter

@DareBioscience

Next Earnings Date

2026-05-12

Latest SEC Filings

DARE's Discussions on Twitter

Compare DARE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DARE Dare Bioscience Inc	3.16	47.61M	1.03M	-13.40M	-10.27M	-1.3314
VRTX Vertex Pharmaceuticals Inc	427.65	107.87B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	721.05	73.63B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	807.55	49.42B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	303.00	40.20B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	313.32	33.06B	5.36B	287.73M	924.18M	2.5229

Dare Bioscience Inc Stock (DARE) Latest News

May 04, 2026

Daré Bioscience (DARE) seeks approval for Lincoln Park share facility and 1.5M-plan increase - Stock Titan

Apr 28, 2026

Apr 27, 2026

Daré outlines expanded dual path strategy targeting $4.5B hormone therapy market while accelerating commercialization in Q4 2025 - MSN

Apr 27, 2026

Apr 26, 2026

Dare Bioscience FY 2025 earnings preview - MSN

Apr 26, 2026

Apr 23, 2026

Daré Bioscience Posts Updated Corporate Investor Presentation Online - The Globe and Mail

Apr 23, 2026

Apr 22, 2026

Daré Bioscience (DARE) posts updated corporate investor presentation - Stock Titan

Apr 22, 2026

Apr 21, 2026

Dare Bioscience completes closing of Regulation A offering of preferred stock and warrants - Investing.com UK

Apr 21, 2026

Apr 20, 2026

Daré Bioscience Completes Regulation A Preferred Stock Offering - TipRanks

Apr 20, 2026

Daré Bioscience (NASDAQ: DARE) closes 20,000-unit Regulation A sale - Stock Titan

Apr 20, 2026

Apr 19, 2026

DARE Surges As Daré Bioscience Unveils Women’s Health Catalysts - StocksToTrade

Apr 19, 2026

DARE Surges As Daré Bioscience Launches Women’s Sildenafil Cream - timothysykes.com

Apr 19, 2026

Apr 18, 2026

DARE Bioscience Jumps As DARE to PLAY Launch and Pipeline Catalysts Draw Focus - StocksToTrade

Apr 18, 2026

DARE Bioscience Jumps As DARE to PLAY Launch Highlights Catalyst Path - timothysykes.com

Apr 18, 2026

Apr 17, 2026

Daré Bioscience Rebalances Classified Board Structure and Terms - TipRanks

Apr 17, 2026

Daré Bioscience (DARE) reclassifies director to rebalance staggered board - Stock Titan

Apr 17, 2026

Daré Bioscience (NASDAQ: DARE) asks shareholders to approve 1.5M plan shares, vote June 11 - Stock Titan

Apr 17, 2026

Apr 16, 2026

12 Health Care Stocks Moving In Thursday's After-Market Session - Benzinga

Apr 16, 2026

Apr 15, 2026

DARE Technical Analysis | Trend, Signals & Chart Patterns | DARE BIOSCIENCE INC (NASDAQ:DARE) - ChartMill

Apr 15, 2026

Apr 14, 2026

Dare Bioscience completes closing of Regulation A equity offering By Investing.com - Investing.com Australia

Apr 14, 2026

DARÉ BIOSCIENCE, INC. Files Form 8-K Report with SEC for Unregistered Sales of Equity Securities – April 2026 - Minichart

Apr 14, 2026

Apr 13, 2026

Dare Bioscience completes closing of Regulation A equity offering - Investing.com

Apr 13, 2026

Daré Bioscience (NASDAQ: DARE) closes Regulation A sale of 3,470 units - Stock Titan

Apr 13, 2026

Apr 11, 2026

Maxim Group Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $8 - Moomoo

Apr 11, 2026

Apr 07, 2026

LEXX Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI

Apr 07, 2026

Apr 03, 2026

Head-To-Head Review: Dare Bioscience (NASDAQ:DARE) & Appili Therapeutics (OTCMKTS:APLIF) - Defense World

Apr 03, 2026

Apr 01, 2026

Maxim Group Upgrades Daré Bioscience (DARE) - MSN

Apr 01, 2026

Dare Bioscience | QUALIF: Others - Moomoo

Apr 01, 2026

Mar 28, 2026